
    
      This is an open-label, fixed-sequence DDI and cardiodynamic study in healthy adult subjects.

      Twenty-six (26), healthy, adult male and female (non-childbearing potential) subjects will be
      enrolled.

      Screening of subjects will occur within 28 days prior to the first dosing.

      To assess the effect of multiple oral doses of edasalonexent on the single-dose
      pharmacokinetics (PK) of midazolam (a cytochrome P450 [CYP]3A4 sensitive substrate) and of
      deflazacort (a CYP3A4 moderate sensitive substrate) in healthy adult subjects.

      Visit assessments include Clinical laboratory tests, Safety ECGs and Cardiodynamic ECGs.
      Subjects will be housed on Day -3 of Period 1, until after the 24-hour blood draw and/or
      study procedures are completed on Day 12 of Period 2.
    
  